Go to content
UR Home

Prediction of immune checkpoint blockade‐related hepatitis in metastatic melanoma patients

URN to cite this document:
DOI to cite this document:
Schilling, Hannah‐Lou ; Hutchinson, James A. ; Haferkamp, Sebastian
License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
Date of publication of this fulltext: 21 Jun 2022 05:07

This publication is part of the DEAL contract with Wiley.


The introduction of clinical antibodies against programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has revolutionized cancer treatment. Immune checkpoint blockade has enormous therapeutic potential and is widely prescribed for treating various cancers. However, immune-related adverse events in checkpoint blockade-treated patients are common and limit its clinical ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons